Additional possibilities of antihypertensive therapy for metabolic syndrome
Abstract
About the Authors
O. A. KislyakRussian Federation
M. V. Pokhilchenko
Russian Federation
References
1. Alberti K, Zimmet P.Z, Shaw J.E. The metabolic syndrome – a new world - wide definition from the International Diabetes Federation Consensus. Lancet 2005; 366: 1059–62.
2. Ishikawa J, Haimoto H, Hoshide S et al. An increased visceral - subcutaneus adipose tissue ratio associated with difficult - to - treatment hypertension in men. Hypertension 2010; 28: 1340–6.
3. Ford E.S, Li C, Sattar N. Metabolic syndrome and incident diabetes. Current state of evidence. Diabetes Care 2008; 31: 1898–904.
4. Salminen M, Kuoppamaki M, Vahlberg T et al. Diabetes Vasc Disease Res 2013; 10: 11–7.
5. Российское медицинское общество по артериальной гипертонии (РМОАГ), Всероссийское научное общество кардиологов (ВНОК). Диагностика и лечение артериальной гипертензии. Российские рекомендации (четвертый пересмотр). Системные гипертензии. 2010; 3: 5–26.
6. Engeli S, Gorzelniak K, Kreutz R et al. Co - expression of renin - angiotensin system genes in human adipose tissue. J Hypertens 1999; 17: 555–60.
7. Lucius R, Galliant S, Busche S et al. Beyond blood pressure: new roles for angiotensin II. Cell Mol Life Sci 1999; 56: 1008–19.
8. Koh K.K, Quon M.J, Han S.H et al. Additive beneficial effects of losartan combined with simvastatin in the treatment of hypercholesteronemic, hypertensive patients. Circulation 2004; 110: 3687–92.
9. Uchida Т, Shimizu М, Sakai Y et al. Effects of losartan on serum total and high – molecular weight adiponectin concentrations in hypertensive patients with metabolic syndrome. J Metabolism 2008; 57: 1278–85.
10. Elliott W.J, Meyer P.M. Incident diabetes in clinical trials of antihypertensive drugs: a network meta - analysis. Lancet 2007; 369: 201–7.
11. Dahlöf B, Devereux R.B, Kjeldsen S.E et al. LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995–1003.
12. Miura S, Karnik S, Saku K. Angiotensin II type 1 receptor blockers: class effects versus molecular effects. JRAAS 2011; 12: 1–8.
13. Подзолков В.И., Булатов В.А. Эффективность лозартана у больных артериальной гипертензией с высоким риском сердечно - сосудистых осложнений (по материалам исследований LIFE и RENAAL). Фарматека. 2004; 6.
14. Oyama C, Takahashi T, Oyamada M et al. Serum uric acid as an obesity - related indicator in early adolescence. J Exp Med 2006; 209: 257–62.
15. Nakagawa T, Hu H, Zharikov S et al. A causal role for uric acid in fructose - induced metabolic syndrome. Am J Physiol Renal Physiol 2006; 290: F625–F631.
16. Feig D.I, Soletsky B, Johnson R.J et al. Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial. JAMA 2008; 300: 924–32.
17. Атюнина И.В., Ощепкова Е.В., Федорович А.А. и др. Мочевая кислота и функция эндотелия микроциркуляторного русла у больных на ранних стадиях артериальной гипертонии. Системные гипертензии. 2012; 2: 29–33.
Review
For citations:
Kislyak O.A., Pokhilchenko M.V. Additional possibilities of antihypertensive therapy for metabolic syndrome. Systemic Hypertension. 2013;10(2):41-46.
Email this article 